NasdaqGS:ZVRAPharmaceuticals
Zevra Therapeutics (ZVRA) Is Down 25.4% After EMA Rejects Arimoclomol MAA In NPC Re-Examination Bid
In July 2026, Zevra Therapeutics reported that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on the Marketing Authorization Application for arimoclomol in Niemann-Pick disease type C, prompting the company to seek a formal re-examination while maintaining patient access through its global Expanded Access Program.
The updated international Consensus Clinical Management Guidelines for Niemann-Pick disease type C highlight arimoclomol...